1. ALLA AKTIER
  2. NYHETER
  3. LUMITO

Lumito

Nyheter Lumito Nyheter alla bolag
Hej Visste du att du med vår premiumtjänst får fullständig historik i alla grafer, pressmeddelanden och andra notiser för dina favoritbolag direkt som DM i Discord samt en del andra godsaker? Du slipper dessutom störande annonser på sajten. Testa gratis i 14 dagar!

Invitation to webinar in connection with Lumito AB’s interim report for Q1 2026

MARKN.

Lumito AB (publ) (“Lumito” or the “Company”) will publish its Q1 report for 2026 on 7 May 2026. In connection with the publication, shareholders, investors, and other stakeholders are invited to a webinar on the same day at 14:30 CET.

During the session, the Company’s CEO, Sanna Wallenborg, will provide a brief introduction to Lumito and summarise the key events of the quarter. This will be followed by an overview of the financial results for the period. The webinar will conclude with a Q&A session, during which Sanna Wallenborg and CFO Fata Mrsic will answer questions submitted in advance via ir@lumito.se.
 
The presentation will be held in Swedish.
A recording of the webinar, including the Q&A, will be made available on the Company’s website after the event.
 
Date and time: 7 May 2026 at 14:30 CET
Registration: https://events.teams.microsoft.com/event/8a543cee-0570-440d-ae86-ea4861a26e82@93b12032-4992-4d22-8a2c-445707f886f0

For further information, please contact:

Sanna Wallenborg, CEO Lumito
E-mail: sw@lumito.se
Ph: +4670-870 01 68

About Lumito
Lumito specialises in medical technology and translational research in digital tissue imaging. Lumito offers a groundbreaking, highly sensitive imaging technique to locate and measure protein biomarkers in tissue samples using up-converting nanoparticles (UCNPs) through its patented research platform. The technology combines image data with precise biomarker detection, enabling images with higher contrast where irrelevant background information is filtered out. The technique can enhance the analysis of tissue samples by increasing objectivity, thereby contributing to research for more quantifiable diagnoses and optimised treatments. Lumito primarily focuses on drug development and digital pathology and is a spin-off from a research group at Lund University's Department of Atomic Physics and Laser Center. www.lumito.se/en/

The share is traded on NGM Nordic SME under the name LUMITO, and Mentor is Mangold Fondkommission.

Attachments
Invitation to webinar in connection with Lumito AB’s interim report for Q1 2026

Datum 2026-05-05, kl 11:00
Källa MFN
Bifogade filer
Invitation to webinar in connection with Lumito AB’s interim report for Q1 2026